AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1130311 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 supplementation (0.8, 2.0, or 20.0 mg of pyridoxine hydrochloride)
Number of subjects: 24
Study 1130311 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6-deficient diet
Number of subjects: 24
Study 29114999 — intervention group
Group type: EXPERIMENTAL
Intervention: Site assessment
Number of subjects: 89
Study 29114999 — intervention group
Group type: COMPARATOR
Intervention: Central assessment
Number of subjects: 89
Study 29114999 — intervention group
Group type: COMPARATOR
Intervention: Central review
Number of subjects: 89
Study 28376149 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy (conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg)
Number of subjects: 907
Study 28376149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 907
Study 25355722 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 991
Study 25355722 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine (XL)
Number of subjects: 991
Study 22827235 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive health priming intervention
Number of subjects: 43
Study 22827235 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 21399467 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreamed Femoral Nail (UFN; Synthes, Bettlach, Switzerland) inserted at the trochanteric fossa
Number of subjects: 17
Study 21399467 — intervention group
Group type: COMPARATOR
Intervention: Long Proximal Femoral Nail (PFN; Synthes) inserted at the tip of the greater trochanter
Number of subjects: 17
Study 18598819 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided (WFG) LASIK
Number of subjects: 0
Study 17174179 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose paclitaxel (1.28 microg/mm2)
Number of subjects: 53
Study 17174179 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose paclitaxel (3.10 microg/mm2)
Number of subjects: 53
Study 17174179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 14559762 — intervention group
Group type: EXPERIMENTAL
Intervention: I1 - Standard logistic regression ignoring clustering
Number of subjects: 0
Study 14559762 — intervention group
Group type: EXPERIMENTAL
Intervention: I4 - Random-effects logistic regression
Number of subjects: 0
Study 14559762 — intervention group
Group type: COMPARATOR
Intervention: C1 - Unweighted regression of practice log odds
Number of subjects: 0
Study 14559762 — intervention group
Group type: COMPARATOR
Intervention: C2 - Regression of log odds weighted by their inverse variance
Number of subjects: 0
Study 14559762 — intervention group
Group type: COMPARATOR
Intervention: C3 - Random-effects meta-regression of log odds with practice as a random effect
Number of subjects: 0
Study 14559762 — intervention group
Group type: EXPERIMENTAL
Intervention: I2 - Robust SE
Number of subjects: 0
Study 14559762 — intervention group
Group type: EXPERIMENTAL
Intervention: I3 - Generalized estimating equations
Number of subjects: 0
Study 14559762 — intervention group
Group type: EXPERIMENTAL
Intervention: I5 - Bayesian random-effects logistic regression
Number of subjects: 0
Study 10691585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (60 mg)
Number of subjects: 40
Study 10691585 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 40
Study 10691585 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (approximately 0.1% blood alcohol concentration)
Number of subjects: 40
Study 10691585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10691585 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 40
Study 10691585 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 40
Study 10691585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 40
Study 8643884 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized treatment (734 patients, 35% of total)
Number of subjects: 2084
Study 8643884 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized treatment (1350 patients, 65% of total)
Number of subjects: 2084
Study 1315590 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization and chemoembolization using microencapsulated Mitomycin
Number of subjects: 32
Study 1315590 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study 3908262 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg mane
Number of subjects: 518
Study 3908262 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 518
Study 29522830 — intervention group
Group type: COMPARATOR
Intervention: Facilitator-led learning
Number of subjects: 240
Study 29522830 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-learning without supervision
Number of subjects: 240
Study 27177587 — intervention group
Group type: EXPERIMENTAL
Intervention: Speckle tracking echocardiography (STE)
Number of subjects: 33
Study 27177587 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional echocardiography (LVEF)
Number of subjects: 33
Study 27177587 — intervention group
Group type: COMPARATOR
Intervention: Conventional echocardiography (SOFA score)
Number of subjects: 33
Study 27177587 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional echocardiography (mean arterial pressure)
Number of subjects: 33
Study 27177587 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional echocardiography (heart rate)
Number of subjects: 33
Study 27177587 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional echocardiography (cardiac output)
Number of subjects: 33
Study 27177587 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional echocardiography (systemic vascular resistance)
Number of subjects: 33
Study 22767005 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (1 L the night before and 1 L on the day of the exam) with bisacodyl 10 mg
Number of subjects: 100
Study 22767005 — intervention group
Group type: COMPARATOR
Intervention: Mannitol (1 L of a 10% mannitol solution on the day of the exam) with bisacodyl 20 mg
Number of subjects: 100
Study 20666948 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen + progestin therapy (HT)
Number of subjects: 32
Study 20666948 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 32
Study 18363588 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy 1 of ART delivery
Number of subjects: 0
Study 18363588 — intervention group
Group type: COMPARATOR
Intervention: Strategy 2 of ART delivery
Number of subjects: 0
Study 16181878 — intervention group
Group type: COMPARATOR
Intervention: Low dose AF0144 (1.8 g/kg)
Number of subjects: 36
Study 16181878 — intervention group
Group type: COMPARATOR
Intervention: High dose AF0144 (2.7 g/kg)
Number of subjects: 36
Study 12108859 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 48
Study 12108859 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 48
Study 10438376 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC‐CMV(gB)
Number of subjects: 20
Study 10438376 — intervention group
Group type: COMPARATOR
Intervention: ALVAC‐RG
Number of subjects: 20
Study 7774741 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 10 units
Number of subjects: 2040
Study 7774741 — intervention group
Group type: COMPARATOR
Intervention: Syntometrine 1 ml (oxytocin 5 units + ergometrine 0.5 mg)
Number of subjects: 2040
Study 2191071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nopharmacological treatment group
Number of subjects: 91
Study 2191071 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 377620 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretransplant blood transfusions
Number of subjects: 0
Study 377620 — intervention group
Group type: COMPARATOR
Intervention: Deliberate transfusion pretreatment
Number of subjects: 0
Study 31066315 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional mirror therapy (4 weeks)
Number of subjects: 51
Study 31066315 — intervention group
Group type: EXPERIMENTAL
Intervention: Teletreatment (6 weeks)
Number of subjects: 51
Study 31066315 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-delivered mirror therapy (6 weeks)
Number of subjects: 51
Study 31066315 — intervention group
Group type: EXPERIMENTAL
Intervention: Teletreatment usage
Number of subjects: 51
Study 31066315 — intervention group
Group type: EXPERIMENTAL
Intervention: Teletreatment user acceptance
Number of subjects: 51
Study 31066315 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers for implementation of teletreatment
Number of subjects: 51
Study 27941333 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic portal reocclusion
Number of subjects: 200
Study 27941333 — intervention group
Group type: COMPARATOR
Intervention: Traditional procedure (Control)
Number of subjects: 200
Study 26285020 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-containing supplement (CAF)
Number of subjects: 12
Study 24343092 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV(+)ARV(−)
Number of subjects: 75
Study 24343092 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV(+)ARV(+)
Number of subjects: 75
Study 24343092 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV therapy longer than 2 years
Number of subjects: 75
Study 24343092 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 75
Study 24343092 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected lipodystrophic patients
Number of subjects: 75
Study 24343092 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study 19615730 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines-based optimal asthma management over 46 weeks
Number of subjects: 546
Study 19615730 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines-based optimal asthma management
Number of subjects: 546
Study 17240224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg orally, 4 x daily for 3 days)
Number of subjects: 12
Study 17240224 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg orally, 4 x daily for 3 days)
Number of subjects: 12
Study 17240224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15878195 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron beam irradiation at 25, 100, and 200 kGy
Number of subjects: 200
Study 15878195 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiated specimens
Number of subjects: 200
Study 12477059 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile idiopathic arthritis (JIA) patients
Number of subjects: 17
Study 12477059 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 17
Study 9402612 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 31
Study 9402612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 7957450 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of theophylline
Number of subjects: 2
Study 3303983 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam inhalation (two 20-minute sessions of inhaling saturated, hot air at 42-44 degrees C)
Number of subjects: 62
Study 3303983 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control group)
Number of subjects: 62
Study 31325396 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban area students
Number of subjects: 5620
Study 31325396 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural area students
Number of subjects: 5620
Study 31325396 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural girls
Number of subjects: 5620
Study 29936590 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.2-0.4 μg/kg/min)
Number of subjects: 40
Study 29936590 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (10-20 μg/kg/min)
Number of subjects: 40
Study 26322438 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC training (6 sessions, 16.5 hours over 9 months)
Number of subjects: 70
Study 25196061 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 μg PEG‐IFNα‐2a weekly
Number of subjects: 56
Study 25196061 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 μg PEG‐IFNα‐2a weekly
Number of subjects: 56
Study 25196061 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2a treatment with HCV RNA negativation at 4 weeks
Number of subjects: 56
Study 25196061 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2a treatment with HCV RNA positivity at 24 weeks
Number of subjects: 56
Study 25196061 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 56
Study 25196061 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment discontinuation due to adverse events
Number of subjects: 56
Study 22843377 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT)
Number of subjects: 97
Study 22843377 — intervention group
Group type: COMPARATOR
Intervention: Primary alternating CRT or concurrent CRT (non-ICT)
Number of subjects: 97
Study 22843377 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy (CRT)
Number of subjects: 97
Study 20016011 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified milk (FM); Daily portion contained 5.28 mg Fe (ferrous gluconate) and 48 mg sodium ascorbate
Number of subjects: 567
Study 20016011 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified milk (NFM); Control group
Number of subjects: 567
Study 20016011 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified milk (FM)
Number of subjects: 567
Study 17573492 — intervention group
Group type: EXPERIMENTAL
Intervention: Good compliance to CPAP treatment (n = 20)
Number of subjects: 53
Study 17573492 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor compliance to CPAP treatment (n = 19)
Number of subjects: 53
Study 17573492 — intervention group
Group type: COMPARATOR
Intervention: Refusal of CPAP treatment (n = 14)
Number of subjects: 53
Study 16213352 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose histidine-tryptophan-ketoglutarate (HTK) solution
Number of subjects: 21
Study 16213352 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 21
Study 12734238 — intervention group
Group type: EXPERIMENTAL
Intervention: BACTEC 13A
Number of subjects: 600
Study 12734238 — intervention group
Group type: EXPERIMENTAL
Intervention: BACTEC MYCO/F LYTIC
Number of subjects: 600
Study 12734238 — intervention group
Group type: EXPERIMENTAL
Intervention: BacT/ALERT MB
Number of subjects: 600
Study 12734238 — intervention group
Group type: EXPERIMENTAL
Intervention: ISOLATOR 10
Number of subjects: 600
Study 9557112 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater saphenous vein segments from women with varicose veins
Number of subjects: 8
Study 9557112 — intervention group
Group type: COMPARATOR
Intervention: Greater saphenous vein segments from women undergoing femoro‐popliteal venous bypass (control group)
Number of subjects: 8
Study 9557112 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis for oestrogen and progesterone receptors
Number of subjects: 8
Study 8238223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens Opacities Classification System II
Number of subjects: 555
Study 8238223 — intervention group
Group type: COMPARATOR
Intervention: Lensmeter 701
Number of subjects: 555
Study 3920695 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI, 150 mg/day for 28 days)
Number of subjects: 33
Study 3920695 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT, dosage not specified for 28 days)
Number of subjects: 33
Study 3920695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not specified)
Number of subjects: 33
Study 3069519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (10-40 mg/day)
Number of subjects: 107
Study 3069519 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1000-4000 mg/day)/codeine (60-240 mg/day)
Number of subjects: 107
Study 3069519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 107
Study 3069519 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol/codeine
Number of subjects: 107
Study 30476217 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular diet mixed with a commercial synbiotic product at 1.0 g/kg (1.0X)
Number of subjects: 360
Study 30476217 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular diet mixed with a commercial synbiotic product at 0.5 g/kg (0.5X)
Number of subjects: 360
Study 30476217 — intervention group
Group type: COMPARATOR
Intervention: Regular diet (control)
Number of subjects: 360
Study 28789467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal ES (CG)
Number of subjects: 63
Study 28789467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal+anodal ES (CAG)
Number of subjects: 63
Study 28789467 — intervention group
Group type: COMPARATOR
Intervention: Placebo ES (PG)
Number of subjects: 63
Study 26337266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM)
Number of subjects: 224
Study 26337266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel (PYR)
Number of subjects: 224
Study 23437909 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose SST (250 μg bolus + continuous infusion of 250 μg/h)
Number of subjects: 41
Study 23437909 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose SST (500 μg bolus + continuous infusion of 250 μg/h)
Number of subjects: 41
Study 23437909 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose SST (250 μg bolus + continuous infusion of 500 μg/h)
Number of subjects: 41
Study 23437909 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo saline injection + placebo infusion)
Number of subjects: 41
Study 21300674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 209
Study 19894302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereton 1000 mg intramuscular for 15 days
Number of subjects: 40
Study 19894302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16550887 — intervention group
Group type: EXPERIMENTAL
Intervention: Project adventure (intervention group)
Number of subjects: 122
Study 16550887 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional physical education)
Number of subjects: 122
Study 15290411 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) with cuff deflated
Number of subjects: 86
Study 15290411 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) with cuff inflated
Number of subjects: 86
Study 15290411 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube (TT)
Number of subjects: 86
Study 11199186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy
Number of subjects: 152
Study 11199186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 9050731 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative laparoscopy with 13CO2 laser vaporization and/or resection
Number of subjects: 176
Study 9050731 — intervention group
Group type: COMPARATOR
Intervention: Operative laparoscopy with simple monopolar electrocoagulation
Number of subjects: 176
Study 9050731 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic laparoscopy without treatment
Number of subjects: 176
Study 9050731 — intervention group
Group type: COMPARATOR
Intervention: Danazol 800 mg/day for 3 months after diagnostic laparoscopy
Number of subjects: 176
Study 8140183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400 IU)
Number of subjects: 250
Study 8140183 — intervention group
Group type: COMPARATOR
Intervention: Control (no vitamin D supplementation)
Number of subjects: 250
Study 3943883 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-methyldopa (500 mg oral dose)
Number of subjects: 5
Study 3943883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 5
Study 30441841 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening meal (1700 h)
Number of subjects: 19
Study 30441841 — intervention group
Group type: COMPARATOR
Intervention: Morning meal (0900 h)
Number of subjects: 19
Study 27470026 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 200 mg and ritonavir 100 mg (low dose)
Number of subjects: 559
Study 27470026 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir 300 mg and ritonavir 100 mg (standard dose)
Number of subjects: 559
Study 24643378 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-S
Number of subjects: 122
Study 24643378 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 122
Study 22115409 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmakinetic
Number of subjects: 101
Study 22115409 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 101
Study 19903683 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (7 cm H2O for 30 min) after acute altitude exposure (CM)
Number of subjects: 2
Study 19903683 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (7 cm H2O for 30 min) after prolonged altitude exposure (MEBC)
Number of subjects: 2
Study 18953082 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril/hydrochlorothiazide with ibuprofen
Number of subjects: 88
Study 18953082 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril/hydrochlorothiazide with piroxicam
Number of subjects: 88
Study 18953082 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril/hydrochlorothiazide with acetaminophen
Number of subjects: 88
Study 18953082 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril/hydrochlorothiazide with ibuprofen or piroxicam (second exposition)
Number of subjects: 88
Study 18953082 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine with ibuprofen or piroxicam
Number of subjects: 88
Study 18953082 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 88
Study 15987289 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day
Number of subjects: 151
Study 15987289 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/week
Number of subjects: 151
Study 15987289 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/week
Number of subjects: 151